[
Roche Holding licensed a new weight-loss drug from Zealand Pharma, bolstering the drugmaker’s effort to get into a hot market dominated by Novo Nordisk and Eli Lilly & Co. Read More
https://fortune.com/img-assets/wp-content/uploads/2025/03/GettyImages-2168395841-e1741775056131.jpg?resize=1200,600
https://fortune.com/europe/2025/03/12/roche-zealand-pharma-5-3-billion-pact-obesity-drugs-novo-nordisk-eli-lilly/
Paula Doenecke, Naomi Kresge, Bloomberg
Roche, Zealand Pharma in $5.3 billion pact for obesity drugs
Related articles
